**SIGIRR Genetic Variants in Premature Infants With Necrotizing Enterocolitis**

Venkatesh Sampath, MD<sup>a,b</sup>, Heather Menden, MS<sup>a</sup>, Daniel Helbling, MS<sup>a</sup>, Keguo Li, PhD<sup>d</sup>, Adam Gastonguay, PhD<sup>d</sup>, Ramani Ramchandran, PhD<sup>d</sup>, David P. Dimmock, MD<sup>c</sup>

---

**abstract**

Necrotizing enterocolitis (NEC) is a severe form of bowel disease that develops in premature infants. Although animal data and human studies suggest that aberrant activation of the intestinal immune system contributes to NEC, the pathogenesis remains unclear. We hypothesized that inherited defects in the regulation of Toll-like receptor signaling can contribute to NEC susceptibility in premature infants. A forward genetic screen done in an infant with lethal NEC using exome sequencing identified a novel stop mutation (p.Y168X) and a rare missense variant (p.S80Y) in SIGIRR, a gene that inhibits intestinal Toll-like receptor signaling. Functional studies carried out in human embryonic kidney cells and intestinal epithelial cells demonstrated that SIGIRR inhibited inflammation induced by lipopolysaccharide, a cell wall component of Gram-negative bacteria implicated in NEC. The genetic variants identified in the infant with NEC resulted in loss of SIGIRR function and exaggerated inflammation in response to lipopolysaccharide. Additionally, Sanger sequencing identified missense, stop, or splice region SIGIRR variants in 10 of 17 premature infants with stage II+ NEC. To the best of our knowledge, this is one of the first reports of a phenotype associated with SIGIRR in humans. Our data provide novel mechanistic insight into the probable causation of NEC and support additional investigation of the hypothesis that inherited defects in the regulation of innate immune signaling can contribute to NEC susceptibility in premature infants.

---

**CASE REPORT**

Infants were recruited under the auspices of an institutional review board–approved study to investigate the impact of genetic variation on diseases of prematurity. After informed consent was obtained, a blood sample was collected for DNA extraction.

---

**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** V.S. and H.M. are supported in part by grant 8KL2TR000056, Clinical and Translational Science Institute of Southeast Wisconsin, and V.S. is supported by Children's Research Institute funds. A.G., K.L., and R.R. are partially supported by National Institutes of Health grants HL09712, HL102745, and HL112639 and by Children's Research Institute startup funds. Funded by the National Institutes of Health (NIH).

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.
Deidentified clinical data were stored in a password-protected database.

**Exome Capture and Analysis**

We extracted DNA from blood samples by using the FlexiGene DNA kit (Qiagen, Inc, Alameda, CA). We performed exome capture by using 5 μg of genomic DNA with the Agilent v4 Exome capture kit (Agilent, Inc, Santa Clara, CA). The captured fragments were sequenced on the HiSeq 2000 with Illumina’s TruSeq technology (Illumina, Inc, San Diego, CA) to an average depth of >40 reads per target base. Image files were processed into binary read files, transferred to an analysis server, and aligned to the human reference sequence hg19/GRCh37 via the Illumina CASAVA pipeline. Variants with respect to GRCh37 were identified and imported into our clinical laboratory’s variant annotation tool “Carpe Novo” and then annotated for functional impact.

**Statistical Analysis**

Data are represented as mean ± SD. Changes in nuclear factor-κ-light-chain-enhancer of activated B cells (NF-κB) activation with lipopolysaccharide (LPS) were expressed relative to controls and compared between groups through analysis of variance (ANOVA). For interleukin-8 (IL-8) protein levels, absolute values were compared between groups through ANOVA. Interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS) RNA levels were expressed as a fold-change relative to controls and analyzed with ANOVA. The post hoc Tukey test was used in conjunction with ANOVA to correct for multiple comparisons. A \( P < .05 \) was considered significant.

**Modeling Approach to Demonstrate Increased Prevalence of SIGIRR Variants in Infants With NEC**

To determine whether there is a greater prevalence of potentially deleterious SIGIRR variants in infants with NEC when compared with the general population, we used the strategy recommended by MacArthur et al.\(^6\) We constructed a variation site frequency spectrum (SFS) of SIGIRR variants from the exome variant server control cohort. The null model of the SFS considers identifying the pathogenic classes of variant present in that gene in the control cohort and calculating the probability of sampling variants of the same class of pathogenicity in the study population. Specifically, we evaluated the rate of predicted “null mutations,” splice region mutations (ie, a variant occurring within 10 bases of the canonical splice site), and missense variants predicted by PolyPhen-2 to be damaging to the SIGIRR function. Among the 18 cases of NEC we identified 5 potentially deleterious variants (Table 1). Performing the same estimates on the exome variant server cohort, we identified 380 variants (Table 2). In the exome variant server cohort, not all loci had the same allele counts. Therefore, for statistical analysis we took the site with the lowest number of cases as the denominator. Performing a \( \chi^2 \) test \( (P < .001, \) Pearson’s \( \chi^2 \) ) we obtained a significance result.

**RESULTS AND DISCUSSION**

**SIGIRR Mutations in Proband With NEC**

The proband was born at 23 weeks and 4 days’ gestation with a birth weight of 560 g. On day of life (DOL) 50, while on full enteral feeds, the infant developed apneas of increasing severity, with 1 large gastric residual warranting increase in respiratory support. On DOL 51, he was noted to have abdominal distension, and radiography showed diffuse pneumatosis intestinalis. Despite intensive medical care there was clinical deterioration warranting surgery, which revealed NEC totalis with pan-pneumatosis and necrosis. We performed whole exome sequencing followed by variant identification by using the Illumina Hi-Seq 2000 and a custom bioinformatics tool developed in our institution.\(^7\) We screened >19 000 exonic variants to identify complete loss-of-function variants. Variant prioritization based on gene function, relevance to immune signaling, and gastrointestinal disease identified 2 potentially deleterious variants in SIGIRR (NM_021805.2), a gene that inhibits TLR signaling.\(^9,10\) The stop variant (p.Y168X, c.504C>G) is novel because it is not found in >6200 individuals belonging to the National Heart, Lung, and Blood Institute exome cohort (snp.gs.washington.edu/EVS). The other variant (p.S80Y, c.239C>A, rs117739035) has a mean allele frequency (MAF) of ~0.02. We performed Sanger sequencing to confirm the presence of both SIGIRR variants in our proband.

**SIGIRR Variants Result in Unregulated TLR4-Mediated Inflammation**

Activation of TLR4, which senses LPS from Gram-negative bacteria, is posited to be a central event in NEC pathogenesis.\(^3,5,11\) Therefore, we investigated whether SIGIRR variants dysregulated TLR4-mediated inflammation. We carried out functional analyses in human embryonic kidney cell line (HEK293) by using LPS. LPS-induced NF-κB activation (a sign of inflammation) and IL-8 protein expression at 20 hours was strongly inhibited in cells transfected with wild-type SIGIRR (SIG-wT) (Fig 1). Similarly, SIGIRR attenuated LPS-induced IL-6 and iNOS RNA expression at 8 hours (Fig 1). Transfection with mutant SIGIRR (SIG-dM) encoding both variants (p.Y168X and p.S80Y) identified in the infant with NEC abolished SIGIRR function and restored TLR4-mediated NF-κB activation, IL-8, IL-6, and iNOS expression (Fig 1). These data show...
that although SIGIRR inhibits inflammation mediated by bacterial ligands, the variants identified in our proband result in loss of regulation of LPS-mediated inflammation.

To investigate whether SIGIRR variants alter intestinal signaling, we performed studies in IEC-18, a nontransformed small intestinal epithelial cell line. Although SIGIRR (SIG-wT) inhibited LPS-induced NF-κB activation, IL-8, IL-6, and iNOS RNA expression, mutant SIGIRR (SIG-dM) abolished LPS responsiveness (Supplemental Fig 2). Furthermore, SIGIRR mediated inhibition of LPS-induced cleaved caspase-3 expression was abolished with mutant SIGIRR (Supplemental Fig 2). These data show that SIGIRR inhibits TLR4-mediated inflammation and apoptotic signaling in intestinal epithelial cells.

### SIGIRR Variants in Other Infants With NEC

We sequenced the coding region of SIGIRR in 17 premature infants with stage II+ NEC. The distribution of clinical and epidemiologic variables in infants with NEC is shown in Table 1. The twin of our proband who survived stage II NEC had both the p.Y168X and p.S80Y variants. Five infants had the missense p.Q312R variant (rs3210908), 3 had the rare missense p.P115R variant (rs111819059), 1 had the rare splice region variant (rs201897529), and the other 7 did not have missense, splice, stop, or frameshift exonic SIGIRR variants. We modeled the SFS approach to compare the prevalence of potentially deleterious SIGIRR variants among NEC infants (n = 18) with the exome variant server cohort.8 This approach revealed a significant excess of deleterious SIGIRR variants (P < .001) in our cohort compared with the general population (Table 2). Additionally, we sequenced DNA from 20 preterm infants without NEC. We did not find the novel (p.Y168X), rare exonic (p.S80Y, p.P115R), or rare splice region variant (rs201897529). Only the benign, common missense variant (p.Q312R) was found in 4 infants. These data show that functional or rare SIGIRR variants are more common in infants with NEC.

### SIGIRR and NEC

SIGIRR is a major negative regulator of intestinal inflammation mediated by TLRs.9,10,13 However, to the best of our knowledge this is one of the first reports of a phenotype associated with SIGIRR in humans. Of the 2 variants identified in our proband and his twin, the stop variant (p.Y168X) has not been found among the genome of >6000 adults.

---

### Table 1: Distribution of SIGIRR Variants in Infants With Stage II+ NEC

<table>
<thead>
<tr>
<th>Infant</th>
<th>Variant rs Number</th>
<th>Protein Change</th>
<th>MAF</th>
<th>GA, wk</th>
<th>Bwt, g</th>
<th>Gender</th>
<th>Race</th>
<th>Feed Type</th>
<th>PDA</th>
<th>NEC Stage</th>
<th>DOL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Novel and rs117739035</td>
<td>p.Y168X, p.S80Y</td>
<td>Novel, 0.02</td>
<td>23</td>
<td>560</td>
<td>M</td>
<td>AA</td>
<td>BOTH</td>
<td>Yes</td>
<td>3</td>
<td>51</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>29</td>
<td>1340</td>
<td>F</td>
<td>AA</td>
<td>FM</td>
<td>No</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>3b</td>
<td>rs11819059</td>
<td>p.P115R</td>
<td>0.006</td>
<td>26</td>
<td>680</td>
<td>F</td>
<td>Cau</td>
<td>BM</td>
<td>Yes</td>
<td>2</td>
<td>64</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
<td>800</td>
<td>M</td>
<td>Cau</td>
<td>BOTH</td>
<td>Yes</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>5b</td>
<td>rs3210908</td>
<td>p.Q312R</td>
<td>0.18</td>
<td>30</td>
<td>1310</td>
<td>M</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>6b</td>
<td>rs3210908</td>
<td>p.Q312R</td>
<td>0.18</td>
<td>30</td>
<td>1340</td>
<td>M</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
<td>660</td>
<td>M</td>
<td>Cau</td>
<td>BOTH</td>
<td>Yes</td>
<td>2</td>
<td>64</td>
</tr>
<tr>
<td>8</td>
<td>rs3210908</td>
<td>p.Q312R</td>
<td>0.18</td>
<td>29</td>
<td>1475</td>
<td>M</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td>26</td>
<td>850</td>
<td>M</td>
<td>AA</td>
<td>BOTH</td>
<td>Yes</td>
<td>3</td>
<td>26</td>
</tr>
<tr>
<td>10b</td>
<td>Novel and rs117739035</td>
<td>p.Y168X, p.S80Y</td>
<td>Novel, 0.02</td>
<td>23</td>
<td>630</td>
<td>M</td>
<td>AA</td>
<td>BOTH</td>
<td>Yes</td>
<td>2</td>
<td>61</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td>1140</td>
<td>F</td>
<td>AA</td>
<td>BOTH</td>
<td>Yes</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>12</td>
<td>rs11819059</td>
<td>p.P115R</td>
<td>0.006</td>
<td>24</td>
<td>580</td>
<td>M</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>3</td>
<td>16</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td>25</td>
<td>940</td>
<td>M</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>3</td>
<td>14</td>
</tr>
<tr>
<td>14</td>
<td>rs3210908</td>
<td>p.Q312R</td>
<td>0.18</td>
<td>24</td>
<td>780</td>
<td>F</td>
<td>AA</td>
<td>BM</td>
<td>No</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>15</td>
<td>rs201897529</td>
<td></td>
<td></td>
<td>25</td>
<td>780</td>
<td>F</td>
<td>AA</td>
<td>BM</td>
<td>No</td>
<td>3</td>
<td>40</td>
</tr>
<tr>
<td>16</td>
<td>rs11819059</td>
<td>p.P115R</td>
<td>0.006</td>
<td>24</td>
<td>300</td>
<td>F</td>
<td>Cau</td>
<td>BM</td>
<td>Yes</td>
<td>2</td>
<td>65</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td>27</td>
<td>1025</td>
<td>F</td>
<td>Cau</td>
<td>BM</td>
<td>Yes</td>
<td>2</td>
<td>64</td>
</tr>
<tr>
<td>18</td>
<td>rs3210908</td>
<td>p.Q312R</td>
<td>0.18</td>
<td>29</td>
<td>1320</td>
<td>F</td>
<td>Cau</td>
<td>BM</td>
<td>No</td>
<td>2</td>
<td>14</td>
</tr>
</tbody>
</table>

AA, African American; BM, breast milk; BOTH, breast milk and formula feeds; Bwt, birth wt; Cau, Caucasian; DOL, day of life for NEC onset; FM, formula milk; GA, gestational age; PDA, patent ductus arteriosus; rs number, reference single nucleotide polymorphism number.

---

### Table 2: Modeling Approach to Demonstrate Greater Prevalence of SIGIRR Variants in Infants With NEC

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Total Tested</th>
<th>Missense Variants</th>
<th>Splice Region Variants</th>
<th>Stop Variants</th>
<th>Total Deleterious Alleles</th>
<th>Normal Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEC</td>
<td>36</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>5</td>
<td>31</td>
</tr>
<tr>
<td>Exome variant server</td>
<td>12,317</td>
<td>352</td>
<td>27</td>
<td>1</td>
<td>380</td>
<td>11,837</td>
</tr>
</tbody>
</table>

SFS analysis was performed to compare frequency of deleterious SIGIRR alleles in our cohort with the exome variant cohort (see the Methods section for description). This revealed an increase in SIGIRR variants in the NEC cohort compared with the general population (P < .001).
Although the twin of our proband also had both the SIGIRR variants, he survived stage II NEC. Whether differences in their outcomes were caused by presence of other clinical risk factors or the effect of modifier genes remains unclear. Additionally, we found both rare and common missense or splice region variants in 9 of 16 infants with NEC. By comparing the frequency of SIGIRR variants in our cohort with the general population, we found more SIGIRR variants in infants with NEC. Furthermore, among 20 premature infants without NEC, we did not find functional or rare SIGIRR variants. NEC is a complex disease involving interactions between clinical variables, developmental immaturity, gut microbiota, and genetic factors. Although our data support a role for SIGIRR variants in NEC, additional studies are needed to evaluate how SIGIRR variants interact with known risk factors to cause disease. Our functional data suggest that SIGIRR variants may contribute to NEC through loss of inhibition of TLR4-mediated inflammation. Activation of TLR4-mediated inflammation has been implicated in NEC pathogenesis in rodent models and humans. Though consistent with these studies, our data suggest that genetic factors can contribute to selective activation of innate immune pathways in infants with NEC. Similarly, a role for reduced SIGIRR function in NEC has been suggested by Nanthakumar et al, who showed less SIGIRR expression in ileal tissue resected from infants with NEC. We speculate that mucosal injury and gut bacteria elicit unregulated TLR-mediated inflammation in infants with SIGIRR variants causing NEC.

CONCLUSIONS

Our data provide novel insight into the probable causation of NEC and support the hypothesis that inherited...
defects in genes that inhibit intestinal innate immune signaling can contribute to NEC. Adequately powered studies are needed to study the impact of \textit{SIGIRR} variants and variant–clinical variable interactions in the causation of NEC.

\textbf{ACKNOWLEDGMENTS}

We thank Dr Xiaoxia Li, PhD (Cleveland Clinic Foundation, Cleveland, OH), for the wild-type \textit{SIGIRR} plasmid and Dr James Verbsky, MD, PhD (Medical College of Wisconsin, Milwaukee, WI), for the IL-8 antibody. We also thank Dr John M. Routes, MD (Medical College of Wisconsin, Milwaukee, WI), for general guidance. We thank Laura Lane, BSN, and Kathleen Meskin, BSN, for help with clinical data collection.

\textbf{REFERENCES}

SIGIRR Genetic Variants in Premature Infants With Necrotizing Enterocolitis
Venkatesh Sampath, Heather Menden, Daniel Helbling, Keguo Li, Adam Gastonguay, Ramani Ramchandran and David P. Dimmock
Pediatrics 2015;135;e1530
DOI: 10.1542/peds.2014-3386 originally published online May 11, 2015;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/135/6/e1530

Supplementary Material
Supplementary material can be found at:
http://pediatrics.aappublications.org/content/suppl/2015/05/07/peds.2014-3386.DCSupplemental

References
This article cites 17 articles, 1 of which you can access for free at:
http://pediatrics.aappublications.org/content/135/6/e1530.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Fetus/Newborn Infant
http://classic.pediatrics.aappublications.org/cgi/collection/fetus:newborn_infant_sub
Neonatology
http://classic.pediatrics.aappublications.org/cgi/collection/neonatology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2015 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005.
SIGIRR Genetic Variants in Premature Infants With Necrotizing Enterocolitis
Venkatesh Sampath, Heather Menden, Daniel Helbling, Keguo Li, Adam Gastonguay, Ramani Ramchandran and David P. Dimmock
Pediatrics 2015;135;e1530
DOI: 10.1542/peds.2014-3386 originally published online May 11, 2015;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/135/6/e1530